TY - JOUR
T1 - Targeting the transcription factor Myb by small-molecule inhibitors
AU - Uttarkar, Sagar
AU - Frampton, Jonathan
AU - Klempnauer, Karl-heinz
PY - 2017/3/1
Y1 - 2017/3/1
N2 - The transcription factor Myb is a key regulator of hematopoietic cell proliferation, differentiation, and survival and has been implicated in the development of leukemia and several other human cancers. Pharmacological inhibition of Myb is therefore emerging as a potential therapeutic strategy. Recently, the first low-molecular-weight compounds that show Myb inhibitory activity have been identified. Characterization of these compounds suggests disruption of the protein–protein–interaction of Myb and the coactivator p300 as a suitable strategy to inhibit Myb.
AB - The transcription factor Myb is a key regulator of hematopoietic cell proliferation, differentiation, and survival and has been implicated in the development of leukemia and several other human cancers. Pharmacological inhibition of Myb is therefore emerging as a potential therapeutic strategy. Recently, the first low-molecular-weight compounds that show Myb inhibitory activity have been identified. Characterization of these compounds suggests disruption of the protein–protein–interaction of Myb and the coactivator p300 as a suitable strategy to inhibit Myb.
U2 - 10.1016/j.exphem.2016.12.003
DO - 10.1016/j.exphem.2016.12.003
M3 - Article
SN - 0301-472X
VL - 47
SP - 31
EP - 35
JO - Experimental Hematology
JF - Experimental Hematology
ER -
